Early-stage drug development worldwide has nearly doubled over the past decade and shifted from a U.S.-dominated model to a ...

A growing body of research has examined the IRA’s implications for pharmaceutical innovation. Much of this literature has focused on the potential impact on the number of new drug launches, 5, 6 but ...

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

April 1 (Reuters) - The weight-loss drug market is surging, with biotech firms racing to win share in a sector dominated by Novo Nordisk and Eli Lilly. Analysts forecast the industry will generate ...

From survivorship bias to root causes! Researchers have applied AI and machine learning to every stage of the drug development process. This includes identifying targets in the body, screening ...

Early 2026 has brought a series of consequential regulatory moves from the FDA, each reflecting a common thread: the agency ...

Eli Lilly and Co (NYSE:LLY) has entered into a drug discovery collaboration with Insilico Medicine, a clinical-stage ...

Overcoming common challenges with today’s biologics, such as developing devices for high-concentration subcutaneous ...

Moving a potential therapy from the laboratory to the pharmacy has always been a slow, incremental journey. “Drug development is a multi-stage process,” says Nichola McCann, associate principal ...

NorthSea Therapeutics B.V. (“NorthSea” or the “Company”), a private, late-stage clinical biotechnology company leveraging its proprietary structurally engineered fatty acids (SEFAs) platform to ...

When patient safety, regulatory approval and real-world effectiveness are on the line, AI can't act autonomously.